People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(MENAFN- EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Spravato, previously ...

According to J&J, Spravato is an N-methyl-D-aspartate (NMDA ... “Ketamine is a safe medication when used under appropriate professional supervision, so FDA approval will lead to a safer ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Spravato targets the neurotransmitter glutamate; however, the mechanism by which esketamine exerts its antidepressant effect is unknown. In an effort to ensure the safe and appropriate use of Spravato ...